Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)

Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)

Summary

"Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)", briefing contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) disease market, together with analysis of current & potential future product positioning.

Key Highlights of the report -

• Development of PBI-4050 is expected to be delayed, due to Prometic’s need for financing, potentially losing its first mover position vs. FibroGen & Galapagos, which have already announced the timeline for their respective Phase III trials.


• FibroGen’s pamrevlumab is expected to be the second novel candidate to achieve approval in IPF (pending successful Phase III trials), and its approval could be accelerated due to the fast track designation in the US.


• Promedior’s PRM-151 is expected to be the third novel therapy to be approved in IPF, however, Promedior did not provide a clear timeline for Phase III trial initiation, suggesting a potential delay in its development.

Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF) report comprises five key sections:

Executive Summary: Contains analysis of key market events that have occurred during the previous quarter and which have impacted the Idiopathic Pulmonary Fibrosis (IPF) landscape.

Landscape Updates -

• ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.


• Timeline forecasts for each approved product’s lifecycle management initiatives.

Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.

Approved Product Landscape: An overview of approved candidates, containing snapshots of current development status

Appendix -

• Current Early Stage IPF Pipeline ‘Watch List’ and discontinued/inactive candidate list.


• Timeline Assumptions, including standard & drug-specific assumptions.


• Glossary and notes on landscape inclusion criteria.

Scope

• The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)


• Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix


• Forecasts are presented in pipeline forecast figures & detailed tables


• ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

• Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher


• Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market


• Reviews ongoing lifecycle management strategies for existing players in the market


• A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.